Alemtuzumab Comparison with Rituximab and Leukemia Whole Blood Assays in Antibody GA 101 in B-Chronic Lymphocytic Glycoengineered , Anti-CD 20 Monoclonal Mechanism of Action of Type II , and Josée

[1]  G. Salles,et al.  Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL) , 2010 .

[2]  F. Buchegger,et al.  Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. , 2010, Blood.

[3]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[4]  Stephen A. Beers,et al.  Anti-CD20 monoclonal antibodies: historical and future perspectives , 2010, Haematologica.

[5]  G. Salles,et al.  Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia. , 2009 .

[6]  G. Salles,et al.  Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL). , 2009 .

[7]  L. Sehn,et al.  A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease. , 2009 .

[8]  C. Klein,et al.  In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL. , 2009 .

[9]  W. Bodmer,et al.  Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis , 2009, British Journal of Cancer.

[10]  A. Klepfish,et al.  Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma , 2009, Annals of the New York Academy of Sciences.

[11]  T. Illidge,et al.  Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. , 2009, The Journal of clinical investigation.

[12]  T. Robak.  GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. , 2009, Current opinion in investigational drugs.

[13]  A. Sica,et al.  M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro1 , 2009, The Journal of Immunology.

[14]  R. P. Taylor.  Use of fresh frozen plasma to enhance the therapeutic action of rituximab. , 2008, QJM : monthly journal of the Association of Physicians.

[15]  C. Gisselbrecht.  Use of rituximab in diffuse large B‐cell lymphoma in the salvage setting , 2008, British journal of haematology.

[16]  G. Weiner,et al.  Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. , 2008, Blood.

[17]  K. Haas,et al.  Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. , 2008, Blood.

[18]  Bruce D Cheson,et al.  Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. , 2008, The New England journal of medicine.

[19]  M. Lindorfer,et al.  Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. , 2008, Current opinion in immunology.

[20]  G. Weiner,et al.  NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. , 2008, Blood.

[21]  S. Sozzani,et al.  The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab1 , 2007, The Journal of Immunology.

[22]  C. Klein,et al.  Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction. , 2006 .

[23]  Yi Wang.  Complementary therapies for inflammation , 2006, Nature Biotechnology.

[24]  L. Diehl,et al.  Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy1 , 2005, The Journal of Immunology.

[25]  Hervé Watier,et al.  From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.

[26]  Jessica M Malenfant,et al.  CD107a as a functional marker for the identification of natural killer cell activity. , 2004, Journal of immunological methods.

[27]  P. Colombat,et al.  Rituximab-Dependent Cytotoxicity by Natural Killer Cells , 2004, Cancer Research.

[28]  K. Haas,et al.  The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.

[29]  M. Cragg,et al.  Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. , 2004, Blood.

[30]  Michael E. Williams,et al.  Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia1 , 2004, The Journal of Immunology.

[31]  M. Czuczman,et al.  Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  Valeria Grieco,et al.  Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 , 2003, The Journal of Immunology.

[33]  Hasmig B. Jinivizian,et al.  B Cell Complement Receptor 2 Transfer Reaction1 , 2003, The Journal of Immunology.

[34]  G. Hale,et al.  Pharmacokinetics of CAMPATH-1H: assay development and validation. , 2002, Journal of immunological methods.

[35]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[36]  T. Barbui,et al.  CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. , 2001, Blood.

[37]  J. Baars,et al.  Complement activation plays a key role in the side‐effects of rituximab treatment , 2001, British journal of haematology.

[38]  H. Kantarjian,et al.  Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[40]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[41]  H. Etlinger,et al.  the Journal of Immunology , 2006 .

[42]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[43]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Greenwood,et al.  Structural motifs involved in human IgG antibody effector functions , 1993, European journal of immunology.

[45]  N. Van Rooijen,et al.  The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. , 2006, Haematologica.

[46]  M. Introna,et al.  Effect of alemtuzumab on neoplastic B cells. , 2004, Haematologica.